secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-07-17T21:01:30+00:00
Accession:  0001193125-26-307964
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm implements 2026 Leadership Cash Retention Program with $3.715M in total awards to four executives
--------------------------------------------------------------------------------

- CEO Richard Paulson receives $1.725M; CFO Lori Macomber $625K; CMO Reshma Rangwala $725K; CDO Stuart Poulton $640K.
- Program replaces 2026 Annual Bonus Plan guaranteed amounts; awards are lump sum cash.
- Awards subject to repayment if executive leaves before 12 months or 30 days post-corporate event, unless termination is without cause, good reason, death/disability.
- Retention program aims to incentivize key employees during period of expected catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526307964/0001193125-26-307964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526307964/d116036d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-307964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer